Get the Stockscreener App
0.77
8.01%
0.0571
Pre-market:
.77
Celularity Inc stock is traded at $0.77, with a volume of 673.49K.
It is up +8.01% in the last 24 hours and down -4.74% over the past month.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
See More
Previous Close:
$0.7129
Open:
$0.8
24h Volume:
673.49K
Relative Volume:
6.24
Market Cap:
$22.29M
Revenue:
$26.55M
Net Income/Loss:
$-91.72M
P/E Ratio:
-0.2148
EPS:
-3.584
Net Cash Flow:
$-13.25M
1W Performance:
-5.17%
1M Performance:
-4.74%
6M Performance:
-45.00%
1Y Performance:
-56.00%
1-Day Range:
$0.72
$0.9586
1-Week Range:
$0.667
$0.9586
52-Week Range:
$0.667
$4.35
Celularity Inc Stock (CELU) Company Profile
Name
Celularity Inc
Sector
Industry
Phone
(908) 768-2170
Address
170 PARK AVE, FLORHAM PARK
Compare CELU vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CELU
Celularity Inc
|
0.77 | 22.29M | 26.55M | -91.72M | -13.25M | -3.584 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celularity Inc Stock (CELU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-22-22 | Initiated | H.C. Wainwright | Buy |
| Apr-06-22 | Downgrade | Truist | Buy → Hold |
| Jan-28-22 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | Morgan Stanley | Equal-Weight |
View All
Celularity Inc Stock (CELU) Latest News
Celularity Inc. Warrant (CELUW) Holds at $0.01 Amid Minimal Volatility – Key Levels in FocusPCR Moving Average - newsline.com
Celularity Inc. 8-K Filing June 2026: Nasdaq Listing, Company Details, and Securities Information - Minichart
Celularity Faces Nasdaq Listing Compliance Risk After Notice - TipRanks
Celularity receives Nasdaq notice for non-compliance with $35 million market value rule - Investing.com
Celularity Received Notice of Noncompliance - TradingView
[8-K] Celularity Inc Reports Material Event - Stock Titan
Celularity (CELU) Slips 6% as Stock Approaches Key Support at $0.69Price Gap Fill - newsline.com
Celularity Inc. (CELU) Slips 7.4% as Selling Pressure Continues Near Key SupportLow Volatility Picks - newsline.com
CELU - Finviz
Celularity and Fountain Life Announce Availability of Cenplacel-L for Investigational Use Under New Florida Law, Establishing Scalable Pathway for Advancement of Placental-Derived Cell Therapies - The Manila Times
New Florida law lets doctors use placental cell therapy before FDA approval - Stock Titan
Celularity names Rick Gonzalez as chief commercial officer - Investing.com UK
Celularity: Actions Are Intended to Streamline Business and Concentrate Resources >CELU - Moomoo
Celularity refocuses on cell therapy after biomaterials sale - Investing.com
Celularity Appoints Rick Gonzalez as Chief Commercial Officer - TipRanks
Celularity names Rick Gonzalez as Chief Commercial Officer - TradingView
New Celularity (NASDAQ: CELU) CCO to drive cenplacel-L and Lifebank growth - Stock Titan
Celularity refocuses on cell therapy after biomaterials sale By Investing.com - Investing.com UK
Celularity Releases CEO Letter to Shareholders - The Manila Times
Celularity outlines placenta cell therapy push to extend health span - Stock Titan
Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer - geneonline.com
Celularity names Rick Gonzalez as chief commercial officer By Investing.com - Investing.com Australia
Celularity: Taken Important Steps to Sharpen Strategic Focus, Strengthen Fincl Position and Enable Celularity to Pursue the Opportunities Most Closely Aligned With Founding Vision - Moomoo
Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer, Effective May 29, 2026 - marketscreener.com
Celularity Receives Nasdaq Notice Regarding Form 10-Q - marketscreener.com
Celularity face Nasdaq listing rule breach after missing Q1 10-Q SEC filing - MSN
Celularity gets Nasdaq notice for delayed Q1 2026 Form 10-Q filing, must submit compliance plan by July 28. - Pluang
Celularity Inc. Notified of Non-Compliance with Nasdaq Listing Rule Due to Delayed 10-Q Filing - Quiver Quantitative
Nasdaq flags Celularity for missing Q1 2026 10-Q filing - Stock Titan
Celularity Enters Settlement, Restructuring Financing Obligations - TipRanks
Celularityenters settlement agreement with Helena on May 21, 2026 - marketscreener.com
Celularity Settles With Helena; $500,000 Upfront, 5x$100,000 Payments and $2.5M Note Rights - TradingView
Celularity (NASDAQ: CELU) restructures Helena preferred stock deal with cash and note rights - Stock Titan
Celularity Inc. (CELU) Surges 8% to $0.99 as Stock Tests Key ResistanceEarly Entry Signals - The Legal Advocate
Celularity (CELU) Edges Higher: Navigating Key Resistance at $0.97PCR Divergence - thelegaladvocate.com
Why Is Celularity Inc. (GXGX) Stock Up Today? - Meyka
Why Is Celularity Inc. (GXGXW) Stock Down Today? - Meyka
Celularity Delays Quarterly SEC Filing - TipRanks
Celularity (NASDAQ: CELU) notifies SEC of delayed Q1 2026 10-Q - Stock Titan
NexGel Q1 2026 Earnings Call Transcript - MarketBeat
TradingKey - TradingKey
Sequence execs join NEXGEL (NASDAQ: NXGL) board after $5.5M note deal - Stock Titan
Is Celularity (CELU) a value trap or a value play? (Recovers) 2026-05-08Certified Trade Ideas - Newser
The hidden strength in Celularity (CELU) most investors miss (Underperforming) 2026-05-07Viral Trades - Newser
Celularity regains Nasdaq compliance after delayed filing - MSN
After $5.5M deal backing, Sequence executives take 2 NEXGEL board seats - Stock Titan
NEXGEL Appoints Brian Kieser and Kevin Harris from New - GlobeNewswire
NEXGEL Appoints Ian Blackman CFO Amid Celularity Deal - MyChesCo
Celularity Inc. 2025 Annual 10-K Report: Financials, Debt, Equity, and Major Agreements Overview - Minichart
Celularity Announces Filing of Form 10-K, Regains Nasdaq Compliance and Highlights Continued Strategic Transformation - Investing News Network
Stocks to watch on Friday after hours: CTLP, CELU, ULH (CTLP:NASDAQ) - Seeking Alpha
Celularity Inc Stock (CELU) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):